NCT01477333 - Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

UT-15C SR

Initiated at 0.125 mg BID, titrated as clinically indicated.

DRUG

Tyvaso Inhalation Solution

Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline

Trial Locations (6)

Allegheny General Hospital, Pittsburgh

Duke University Medical Center, Durham

The University of Alabama at Birmingham, Birmingham

Mayo Clinic, Rochester

Washington University School of Medicine, St Louis

UT Southwestern Medical Center, Dallas